kojim – KBP Biosciences

Author Archives: kojim

Positive FDA Type B Meeting on KBP-5074

JINAN, China and PRINCETON NJ, USA, January 11, 2017 – – KBP BioSciences Co., Ltd. (“KBP” or the “Company”), a clinical stage biotechnology company dedicated to research, development, and commercialization of innovative medicines for the global market, today announced that it has concluded a positive Type B Meeting with the U.S. Food and Drug Administration

Read More

KBP-7072 obtained QIDP and Fast Track Designations

(Jinan, China, and Princeton, NJ) KBP BioSciences, a clinical stage biopharma company announced today that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for KBP-7072, a new generation tetracycline for resistant bacterial infections. KBP-7072 obtained the QIDP and Fast Track designations based on treatment of community-acquired bacterial

Read More

Promotion of Dr. Fred Yang to Chief Development Officer

April 19, 2016 –Jinan, China –KBP BioSciences announced today that Dr. Fred Yang has been promoted to Chief Development Officer. Dr. Yang joined KBP BioSciences in August 2015 as Senior Vice President, Medical Affairs. Under his new role, Dr. Yang will report to Dr. Zhenhua Huang, Executive Chairman of KBP BioSciences. Dr. Yang’s new assignment

Read More

Presenting At The Upcoming Scientific Conventions

KBP will attend two scientific conferences this coming Spring to present our recent findings. The first one is the NKF Spring Clinical Meetings on April 27th in Boston. A KBP team will have a poster presentation titled “Pharmacological Profile of KBP-5074, A Novel Non-Steroidal, Highly Selective, Mineralocorticoid Receptor Antagonist (MRA) For The Treatment of Cardiorenal

Read More